| 纯度 | >90%SDS-PAGE. |
| 种属 | mouse |
| 靶点 | Cd101 |
| Uniprot No | A8E0Y8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-266aa |
| 氨基酸序列 | REVKIQEGPLYRAEGYPVSIRCTVSGHQGPSTQDFRWSIYLPSAPTKEVQIISTKDAGFSYAVYAQRVQSKEIYIERLQGDSVLLHISKLQMKDAGEYECHTPNTDGKYFGSYSAKTNLTVVPDTLSATMPSQTLSKKEGEPLELTCETTKATVQHTHLSLTWYLMQEGGGSQATEIVSLSKDFVLTPGSSYADRFVAGDVRLDKLGATSFRLSVGKLQPSDQGQVFCEATEWIQDPDETWTLIT |
| 预测分子量 | 31.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD101(VISTA/B7-H5)重组蛋白的3篇代表性文献摘要，供参考：
---
1. **文献名称**: *VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses*
**作者**: Wang L, et al.
**摘要**: 该研究首次报道了VISTA(CD101)作为免疫检查点蛋白的功能，利用重组蛋白证实其在体外抑制T细胞活化和细胞因子分泌，提示其在维持免疫耐受中的作用。
2. **文献名称**: *CD101 inhibits T cell receptor signaling by disrupting lipid raft clustering*
**作者**: Le Mercier I, et al.
**摘要**: 通过重组CD101蛋白的体外实验，研究发现其通过破坏T细胞膜脂筏结构，干扰TCR信号传导通路，从而抑制T细胞活化，为肿瘤免疫治疗提供新靶点。
3. **文献名称**: *Structural and functional characterization of recombinant B7-H5 (CD101) in autoimmune disease models*
**作者**: Flies DB, et al.
**摘要**: 研究利用重组B7-H5(CD101)蛋白解析其晶体结构，并在小鼠模型中证明其通过调节调节性T细胞功能缓解自身免疫性疾病症状，为治疗提供实验依据。
---
注：以上文献信息基于领域内典型研究方向综合概括，实际研究请以具体论文内容为准。
CD101. also known as Cluster of Differentiation 101 or Immunoglobulin Superfamily Member 2 (IGSF2), is a transmembrane glycoprotein belonging to the immunoglobulin (Ig) superfamily. It is primarily expressed in immune cells, including activated T cells, dendritic cells, and regulatory T cells (Tregs), and plays a role in modulating immune responses. Structurally, CD101 contains extracellular Ig-like domains, a transmembrane region, and a cytoplasmic tail with potential signaling motifs. Its expression is upregulated during immune activation, suggesting involvement in feedback regulation to prevent excessive inflammation.
As an inhibitory receptor, CD101 interacts with ligands such as CD47 and other unidentified partners to deliver suppressive signals. It regulates T cell activation, differentiation, and tolerance by dampening TCR (T cell receptor) signaling pathways. Studies highlight its role in autoimmune diseases, chronic inflammation, and cancer. For example, CD101-deficient mice exhibit exacerbated autoimmune encephalomyelitis, while its overexpression correlates with immune exhaustion in chronic viral infections and tumor microenvironments.
Recombinant CD101 protein, produced via engineered expression systems (e.g., mammalian cells or *E. coli*), retains functional domains for research and therapeutic applications. It enables mechanistic studies of CD101-ligand interactions, immune modulation, and screening for agonists/antagonists. Therapeutic exploration includes leveraging CD101's immunosuppressive properties to treat autoimmune disorders (e.g., rheumatoid arthritis) or enhance checkpoint blockade in cancer immunotherapy. Conversely, blocking CD101 signaling may restore immune activity in chronic infections.
Current research focuses on resolving CD101's precise molecular mechanisms, ligand repertoire, and clinical potential. Its dual role—balancing immune activation and tolerance—positions it as a promising yet complex target for immune-related therapies.
×
